NEXENTIS TECHNOLOGIES INC.

NASDAQ: NXTS (Nexentis Technologies Inc.)

最近更新时间: 3天之前, 1:40PM

1.79

0.04 (2.29%)

前收盘价格 1.75
成交量 4,368
价格/销量 (P/S) 116.20
股市价格/股市净资产 (P/B) 0.280
52周波幅
1.70 (-5%) — 119.00 (6548%)

AIStockmoo 评分

-2.4
资本回报低于资本成本。资本回报上升。 参考
来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 NA
相对估值 参考 NA
隐含增长 参考 NA
历史估值 参考 NA
财务健康 参考 NA
盈利趋势 参考 NA
持仓估值 参考 NA
风险溢价 参考 NA
市场估值 参考 NA
过去一年呈下降趋势。股价远低于52周高点。 参考
下降趋势:股价位于均线之下,均线向下。股价接近均线。上涨日成交量较大。 参考
来自我们对走势图的 AI 技术分析。 参考 NA
K线形态 参考 NA
近期没有目标价,因此依据目标价的调整方向。 参考
持仓情绪 参考 NA
新闻情绪 参考 NA
机构在最新13F申报中净-0.58%的股份:3家增持,2家减持(截至30 Sep 2026的季度)。 参考
空头持仓从31 Aug到30 Oct 2026变化+21.3%,回补天数1天(FINRA)。 参考
内部交易活动 参考 NA
市场环境偏谨慎。 参考
行业表现落后大市。
各支柱方向一致,评分因此加强。
低于中期趋势线。 参考
股价低于其52周平均水平。5年来下跌。 参考
短期动能下降。 参考
支撑与阻力水平趋升。 参考
最终评分 -2.43
全部展开

市场趋势

短期 中期
行业 Agricultural Inputs (US) 混合的 混合的
Agricultural Inputs (全球的) 混合的 混合的
股票 Nexentis Technologies Inc. - -

相关股票

股票 市值 DY P/E(TTM) P/B 评分
NXTS - - - 0.280 -2.4
LVRO 35 M - - - -1.6
SEED 9 M - - - -4.3
NITO 3 M - - - 0.0
BIOX 11 M - - 0.370 -4.6

Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.

部门 Basic Materials
行业 Agricultural Inputs
投资方式 Small Value

该时间范围内无数据。

该时间范围内无数据。

机构

机构持股比例: 1.62%

持仓变动 机构数 股数
增持 3 6,225
减持 2 9,178
新建仓 3 6,225
清仓 1 9,048

来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。

空头持仓

结算日 股数 回补天数
30 Oct 2026 63,636 1.0
15 Oct 2026 61,274 1.0
30 Sep 2026 37,720 1.0
15 Sep 2026 39,461 2.3
31 Aug 2026 52,477 1.7
14 Aug 2026 62,682 1.1

来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。

1 正面 0 负面 1 中性
日期 类型 细节
17 Nov 2026 Yahoo Finance Nexentis: MitoCareX Progresses Toward In-Vitro Evaluation Following AI-Powered Computational Screening
Further computational prioritization by MitoCareX leads to selection and ordering of molecules for planned experimental assessment Ness Ziona, Israel, , Nov. 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”) today announced that its wholly owned…
05 Nov 2026 Yahoo Finance Nexentis Announces Reverse Stock Split
Ness Ziona, Israel, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, announced that its Board of Directors has approved a…
29 Oct 2026 Yahoo Finance Nexentis: MitoCareX Completes Initial AI-Powered Computational Screening Milestone with Boltz
MitoCareX considers preliminary, not yet experimentally validated, computational findings encouraging for further computational analysis and experimental investigation Ness Ziona, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”)…
26 Oct 2026 Yahoo Finance Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage
MitoCareX considers preliminary, not yet experimentally validated, computational findings encouraging for further computational analysis and experimental investigation Ness Ziona, Israel, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”) today…
12 Oct 2026 Yahoo Finance Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis
MitoCareX expands its internal bioinformatics expertise to broaden the analysis of disease biology within its computational drug-discovery activities Ness Ziona, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), today announced that…
07 Oct 2026 Yahoo Finance Nexentis Deploys MitoCareX Computational Drug Discovery Infrastructure on Google Cloud
Nexentis subsidiary MitoCareX has moved its computational drug discovery infrastructure to Google Cloud Platform, aiming to improve computing flexibility, scientific data management and research workflows as its discovery programs develop. Key Investor TakeawaysNexentis Technologies (NASDAQ:NXTS)…
07 Oct 2026 Yahoo Finance Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud
Deployment on Google Cloud Platform is designed to enhance computational capacity, data governance and operational flexibility as MitoCareX advances its drug discovery programs Ness Ziona, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis”…
24 Sep 2026 Yahoo Finance Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board
Leading computational chemistry expert to advise MitoCareX as it expands its in silico drug-discovery capabilities Ness Ziona, Israel, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests…
23 Sep 2026 Yahoo Finance Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery
Evaluation of additional commercially available approaches for obtaining proteins is intended to enhance access to research materials, increase research flexibility and support the advancement of MitoCareX’s future in-vitro drug discovery programs Ness Ziona, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE)…

技术形态 中期

趋势排列
斜率
入场位置
成交量
下降趋势:股价位于均线之下,均线向下。股价接近均线。上涨日成交量较大。
最近阻力: 1.83 – 2.02 · 中等

AI 技术分析

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

风险 / 回报
TP1:
TP2:

以入场价计算,止损的亏损相对每个目标价的盈利。通常追求 2 或以上的比率。

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票